File ONCOLOGY_PRIMARY(165.5) Data List

SITE/GP	PRIMARY SITE/GP	SELECTED SITES	SYSTEMS	PATIENT NAME	ICDO-SITE	PRIMARY SITE CODE PREFIX	PATIENT ID	REPORTING FACILITY	CLASS OF CASE	CLASS NO.	CLASS CATEGORY	ANALYTIC PRIMARY REQ FOLLOWUP	ACCESSION NUMBER	SEQUENCE NUMBER	ACC/SEQ NUMBER	ACCESSION YEAR	MEDICAL RECORD NUMBER	SOCIAL SECURITY NUMBER	STATUS	PLACE OF BIRTH (STATE)	SEX	STATE	ST-COUNTY	COUNTY	RACE	RACE-SEX	SEX-RACE	DATE OF INPATIENT ADMISSION	DATE OF INPATIENT DISCHARGE	TYPE OF REPORTING SOURCE	COUNTY AT DX	TEXT-PRIMARY SITE TITLE	ORAL CONTRACEPTIVES	ESTROGEN REPLACEMENT	TAMOXIFEN	OTHER HORMONES	ASCITES	CIRRHOSIS	CHILD'S CLASS A	CHILD'S CLASS B	CHILD'S CLASS C	HEPATITIS B	TEXT-HISTOLOGY TITLE	HEPATITIS C	RX HOSP--SURG BREAST	RX SUMM--SURG BREAST	RX HOSP--RECON BREAST 22-23	RX SUMM--RECON BREAST 22-23	RX HOSP--RECON BREAST	RX SUMM--RECON BREAST	HEMOCHROMATOSIS	ALCOHOL CONSUMPTION	AFP (IU/ml)	CEA (mg/ml)	CA19.9 (U/ml)	PROTIME (sec)	BILIRUBIN (mg/ml)	ALBUMIN (g/dl)	LDH (U/I)	DRE +/-	CT ARTERIAL PORT-PERFORMED	CT ARTERIAL PORT-CIRRHOSIS	CT ARTERIAL PORT-VASCULAR INV	CT ARTERIAL PORT-BILOBAR DIS	CT ARTERIAL PORT-LYMPH NODES	CT ARTERIAL PORT-SIZE OF TUMOR	CT ARTERIAL PORT-NUM 0F TUMORS	SPIRAL CT-PERFORMED	SPIRAL CT-CIRRHOSIS	SPIRAL CT-VASCULAR INV	TEXT-DX PROC-OP	SPIRAL CT-BILOBAR DIS	SPIRAL CT-LYMPH NODES	SPIRAL CT-SIZE OF TUMOR	SPIRAL CT-NUM OF TUMORS	INCREMENTAL CT-PERFORMED	INCREMENTAL CT-CIRRHOSIS	INCREMENTAL CT-VASCULAR INV	INCREMENTAL CT-BILOBAR DIS	INCREMENTAL CT-LYMPH NODES	INCREMENTAL CT-SIZE OF TUMOR	TEXT-DX PROC-PE	INCREMENTAL CT-NUM 0F TUMORS	ULTRASOUND-PERFORMED	ULTRASOUND-CIRRHOSIS	ULTRASOUND-VASCULAR INV	ULTRASOUND-BILOBAR DIS	ULTRASOUND-LYMPH NODES	ULTRASOUND-SIZE OF TUMOR	ULTRASOUND-NUM 0F TUMORS	MRI-PERFORMED	MRI-CIRRHOSIS	TEXT-DX PROC-X-RAY/SCAN	MRI-VASCULAR INV	MRI-BILOBAR DIS	MRI-LYMPH NODES	MRI-SIZE OF TUMOR	MRI-NUM 0F TUMORS	DEFINITIVE DIAGNOSIS	RADIO-FREQUENCY DESTRUCTION	ABLATION & RESECTION	DISTANCE TO CLOSEST MARGIN	ABLATION	TEXT-DX PROC-SCOPES	RESECTION	CISPLATIN	FUDR	5-FU	FU & LEUCOVORIN	IRINOTECAN (CPT-11)	MITOMYCIN C	OXALIPLATIN	GEMCITABINE	ROUTE CHEMO ADMIN	TEXT-DX PROC-PATH	CHEMOTHERAPY/SURGERY SEQUENCE	ARTERIAL EMBOLIZATION	DEATH W/I 30 DAYS START TX	RX TEXT-SURGERY	RX TEXT-RADIATION	MARITAL STATUS AT DX	RX TEXT-RADIATION OTHER	HISTORY OF MELANOMA (PT)	HISTORY OF OTHER CANCER (PT)	FIRST SITE CODE	FIRST SITE DIAGNOSIS DATE	SECOND SITE CODE	SECOND SITE DIAGNOSIS DATE	PREGNANCY AT INITIAL DIAGNOSIS	EXOGENOUS HORMONES	DISEASE PRESENTATION LOCATION	TYPE OF BIOPSY	RX TEXT-CHEMO	EXTRANODAL EXTENSION	MICROSATELLITOSIS	NUMBER OF SATELLITE NODULES	LOCATION OF IN-TRANSIT NODULES	BRESLOW'S THICKNESS	CLARK'S LEVEL OF INVASION	ANGIOLYMPHATIC INVASION	PERINEURAL INVASION	ULCERATION	CLINICALLY AMELANOTIC	RX TEXT-HORMONE	MARGIN DISTANCE (MEL)	SURGICAL CLOSURE	PRE-OP LYMPHOSCINTIGRAPHY	SENTINEL NODES DETECTED BY	SENTINEL NODES EXAMINED (MEL)	SENTINEL NODES POSITIVE (MEL)	METHOD OF PATHOLOGIC EXAM	LYMPH NODE DISSECTION	NUMBER OF BASINS DISSECTED	NUMBER OF BASINS POSITIVE	TEXT-REMARKS	INTRAVENOUS THERAPY	GENE THERAPY	SIZE OF TUMOR (MELANOMA)	RX TEXT-BRM	RX TEXT-OTHER	TEXT-DX PROC-LAB TESTS	OTHER STAGE GROUP	STAGED BY (OTHER STAGE)	SCREENING RESULT	PALLIATIVE CARE	PRESENTATION AT CANCER CONF	HANDEDNESS	HYPERTENSION	MULTIPLE SCLEROSIS (MS)	DIABETES	CEREBROVASCULAR DISEASE	BRAIN	BREAST	PROSTATE	MALIGNANT MELANOMA	OTHER SKIN CANCER	DATE OF CANCER CONF	LEUKEMIA	COLON OR OTHER GI CANCERS	OTHER PERSONAL HISTORY OF CA	NEUROFIBROMATOSIS	VON HIPPEL-LINDAU DISEASE	TUBEROUS SCLEROSIS	TURCOT SYNDROME	LI-FRAUMENI SYNDROME	KOWDEN DISEASE	NEVOID BASAL CELL CARCINOMA	REFERRAL TO SUPPORT SERVICES	HEADACHE	NAUSEA/VOMITING	CHANGE IN SENSE OF SMELL/TASTE	ALTERED ALERTNESS	FATIGUE	SPEECH DISTURBANCE	PERSONALITY CHANGES	DEPRESSION	MEMORY LOSS	LACK OF CONCENTRATION	INPATIENT/OUTPATIENT STATUS	DOUBLE VISION	OTHER VISUAL DISTURBANCE	DECREASED HEARING	VERTIGO	TINNITUS	NUMBNESS/TINGLING	WEAKNESS OR PARALYSIS	DIFFICULTY IN COORD/BALANCE	GENERALIZED SEIZURE	FOCAL SEIZURE	DATE OF NO TREATMENT	BLADDER INCONTINENCE	BOWEL INCONTINENCE	PAIN (OTHER THAN HEADACHE)	WEIGHT CHANGE	OTHER SYMPTOMS	ALERTNESS	SPEECH	PERSONALITY	MEMORY OR JUDGEMENT	VISUAL ACUITY	RADIATION TREATMENT VOLUME	VISUAL FIELDS	EYE MOVEMENTS (EOM)	FACIAL SENSATION	FACIAL MOVEMENT	HEARING	GAG REFLEX	STERNOCLEIDOMASTOID/SHLD STR	ARTICULATION OR ENUNCIATION	PAPILLEDEMA	TONGUE FASCICULATIONS/ATROPHY	LOCATION OF RADIATION TX	DECREASE IN SENSATION/ANY SITE	CORTICAL SENSORY DEFICIT	WEAKNESS/ATROPHY/FASCICULATION	ATAXIA OF GAIT	TRUNCAL ATAXIA	DYSMETRIA	RAPID ALTERNATING MOVEMENTS	FINGER TO FINGER NOSE TESTING	HEEL TO KNEE TO SHIN TESTING	DEEP TENDON REFLEXES/UPPER EXT	INTENT OF RADIATION	DEEP TENDON REFLEXES/LOWER EXT	BABINSKI SIGN	HOFFMAN REFLEX	OTHER ABNORMAL REFLEXES	ANGIOGRAPHY	COMPUTED TOMOGRAPHY (CT) SCAN	CT SCAN OF SPINE	ELECTROENCEPHALOGRAPHY (EEG)	ISOTOPE BRAIN SCAN	POSITRON EMISSION TOMOGRAPHY	RADIATION COMPLETION STATUS	SPECT SCAN	MRI OF BRAIN	MRI OF SPINE	FUNCTIONAL MRI	MYELOGRAPHY	MAGNETIC RES SPECTROSCOPY	FRONTAL LOBE	TEMPORAL LOBE	PARIETAL LOBE	OCCIPITAL LOBE	RADIATION AUXILIARY VOLUME	OPTIC NERVES	PITUITARY GLAND	PINEAL GLAND	CEREBELLUM	BRAIN STEM	SKULL BASE	OTHER SKULL	SPINAL CORD	CEREBRAL SPINAL FLUID (CSF)	CRANIAL MENINGES	PALLIATIVE CARE @FAC	RADIATION AUXILIARY DATE	SPINAL MENINGES	OTHER TUMOR LOC/INVOLVEMENT	LEFT	RIGHT	MIDLINE	NUMBER OF TUMORS	DATE OF FIRST SYMPTOMS	DATE OF PATHOLOGIC DIAGNOSIS	WHO HISTOLOGICAL CL	MOLECULAR MARKERS	RADIATION AUXILIARY TEXT	TUMOR SIZE (SOURCE)	KARNOFSKY'S RATING PRIOR TO TX	PROTOCOL PARTICIPATION (CNS)	PROTOCOL PHASE	NONE, NO NON-CA DIR SURGERY	VENTRICULOSTOMY/EXT VENT DRAIN	CSF SHUNT/VENTRICULOPERITONEAL	CSF SHUNT/3RD VENTRICULOSTOMY	CSF SHUNT/OTHER	STEREOTACTIC BIOPSY	RADIATION LOCAL CONTROL STATUS	OPEN BRAIN BIOPSY	OPEN BX OF SPINCAL CORD TUMOR	LAMINECTOMY W/O RESECT/DURA	LAMINECTOMY W/O RESECT W DURA	SURGERY, NOS	UNKNOWN IF SURGERY DONE	SURGICAL APPROACH (CNS)	EXTENT OF SURGICAL RESECTION	SIZE OF RESIDUAL TUMOR	SIZE OF RES TUMOR (SOURCE)	YEAR PUT ON PROTOCOL	ANESTHETIC PROBLEM	HEMORRHAGE AT OPERATIVE SITE	SEIZURE	INFECTION(S)	DVT (DEEP VENOUS THROMBOSIS)	PERSISTENT NEUROL WORSENING	TOTAL RADIATION DOSE (cGy)	TYPE OF EXT BEAM RADIATION	INTERSTITIAL RAD/BRACHYTHERAPY	STEREOTACTIC RADIOSURGERY	CLINICAL RISK FACTORS	SKIN REACTIONS	ANOREXIA	NAUSEA OR VOMITING	NEUROLOGIC WORSENING	RADIATION THERAPY	PROCARBAZINE	CCNU	VINCRISTINE	HYDROXYUREA	PATHOLOGIC RISK FACTORS	BCNU	BCNU WAFER IMPLANT	VP-16	CARBOPLATIN	TEMOZOLOMIDE	CPT-11	CYTARABINE (ARA-C)	CHEMOTHERAPEUTIC ROUTE	HEARING LOSS	SERUM TUMOR MARKERS	INFECTION	NAUSEA AND VOMITING	BLOOD COUNT DROP/BLEEDING	PERIPHERAL NEUROPATHY	RENAL FAILURE	PULMONARY TOXICITY	OTHER CHEMO COMPLICATIONS	KARNOFSKY'S RATING @ DIS/TRANS	DATE OF PROGRESSION	TYPE OF PROGRESSION	DATE OF 1ST POSITIVE BIOPSY	RECURRENCE/PROGRESSION DOC	KARNOFSKY'S RATING RECURRENCE	TYPE OF 1ST RECURRENCE/CNS	PROTOCOL PARTICIPATION (SUBTX)	TYPE OF SUBSEQUENT SURGICAL TX	TYPE OF SUBSEQUENT RADIATION	PROCARBAZINE (SUB TX)	CCNU (SUB TX)	VINCRISTINE (SUB TX)	HYDROXYUREA (SUB TX)	SCOPE OF LN SURGERY (R)	SCOPE OF LN SURGERY @FAC (R)	SCOPE OF LN SURGERY DATE	SCOPE OF LN SURGERY @FAC DATE	SCOPE OF LN SURGERY (F)	SCOPE OF LN SURGERY @FAC (F)	METHOTREXATE (SUB TX)	CISPLATIN (SUB TX)	BCNU (SUB TX)	BCNU WAFER IMPLANT (SUB TX)	VP-16 (SUB TX)	CARBOPLATIN (SUB TX)	TEMOZOLOMIDE (SUB TX)	CYCLOPHOSPHAMIDE (SUB TX)	CPT-11 (SUB TX)	TAMOXIFEN (SUB TX)	SURG PROC/OTHER SITE (R)	SURG PROC/OTHER SITE @FAC (R)	SURG PROC/OTHER SITE DATE	SURG PROC/OTHER SITE @FAC DATE	SURG PROC/OTHER SITE (F)	SURG PROC/OTHER SITE @FAC (F)	METS SITE RESECTED	METS SITE RESECTED DATE	INTERFERON (SUB TX)	CYTARABINE (ARA-C) (SUB TX)	OTHER CHEMOTHERAPY (SUB TX)	OTHER SUBSEQUENT TREATMENT	TUMOR SIZE	READMISSION W/I 30 DAYS/SURG	NUMBER OF LN REMOVED (R)	NUMBER OF LN REMOVED @FAC (R)	LNG CO-MORBID CONDITION 1	LNG CO-MORBID CONDITION 2	LNG CO-MORBID CONDITION 3	LNG CO-MORBID CONDITION 4	LNG CO-MORBID CONDITION 5	LNG CO-MORBID CONDITION 6	LNG CO-MORBID CONDITION Y/N	LNG DURATION OF TOBACCO USE	LNG DATE OF FIRST TISSUE DX	LNG PERSONAL HIST OTH MALIG	LNG COUGH	LNG SHORTNESS OF BREATH	LNG WEIGHT LOSS	LNG HEMOPTYSIS	LNG PALPABLE LYMPH NODES	LNG CHEST X-RAY	LNG CT SCAN	LNG BRONCHOSCOPY	LNG HISTORY AND PHYSICAL	LNG BRONCHOSCOPY PRE-THERAPY	LNG FNAB	LNG MEDIASTINOSCOPY	LNG THOROCOTOMY/OPEN BIOPSY	LNG VATS	LNG FVC	LNG FEV	LNG LIVER FUNCTION TESTS	LNG BONE SCAN	LNG EMPHYSEMA (BONE SCAN)	LNG VASCULAR INV (BONE SCAN)	LNG MEDIASTINAL LN (BONE SCAN)	LNG TUMOR SIZE (BONE SCAN)	LNG NUM OF TUMORS (BONE SCAN)	LNG METASTASIS (BONE SCAN)	BIOPSY PROCEDURE	LNG CT SCAN OF CHEST	LNG EMPHYSEMA (CHEST CT)	LNG VASCULAR INV (CHEST CT)	LNG MEDIASTINAL LN (CHEST CT)	LNG TUMOR SIZE (CHEST CT)	LNG NUM OF TUMORS (CHEST CT)	LNG METASTASIS (CHEST CT)	LNG CT SCAN OF BRAIN	LNG EMPHYSEMA (BRAIN CT)	LNG VASCULAR INV (BRAIN CT)	LNG MEDIASTINAL LN (BRAIN CT)	LNG TUMOR SIZE (BRAIN CT)	LNG NUM OF TUMORS (BRAIN CT)	LNG METASTASIS (BRAIN CT)	LNG MRI SCAN OF CHEST	LNG EMPHYSEMA (CHEST MRI)	LNG VASCULAR INV (CHEST MRI)	LNG MEDIASTINAL LN (CHEST MRI)	LNG TUMOR SIZE (CHEST MRI)	LNG NUM OF TUMORS (CHEST MRI)	LNG METASTASIS (CHEST MRI)	LNG MRI SCAN OF BRAIN	LNG EMPHYSEMA (BRAIN MRI)	LNG VASCULAR INV (BRAIN MRI)	LNG MEDIASTINAL LN (BRAIN MRI)	LNG TUMOR SIZE (BRAIN MRI)	LNG NUM OF TUMORS (BRAIN MRI)	LNG METASTASIS (BRAIN MRI)	LNG PET SCAN	LNG EMPHYSEMA (PET SCAN)	LNG VASCULAR INV (PET SCAN)	LNG MEDIASTINAL LN (PET SCAN)	LNG TUMOR SIZE (PET SCAN)	LNG NUM OF TUMORS (PET SCAN)	LNG METASTASIS (PET SCAN)	LNG X-RAY OF CHEST	LNG EMPHYSEMA (CHEST XRAY)	LNG VASCULAR INV (CHEST XRAY)	LNG MEDIASTINAL (CHEST XRAY)	LNG TUMOR SIZE (CHEST XRAY)	LNG NUM OF TUMORS (CHEST XRAY)	LNG METASTASIS (CHEST XRAY)	LNG HIGH MEDIASTINAL (PRE-OP)	LNG UPPER PARATRACH (PRE-OP)	LNG PREVASC/RETRO (PRE-OP)	LNG LOWER PARATRACH (PRE-OP)	LNG SUBAORTIC (PRE-OP)	LNG PARAORTIC (PRE-OP)	LNG SUBCARINAL (PRE-OP)	LNG PARAESOPHAGEAL (PRE-OP)	LNG PULMONARY LIG (PRE-OP)	LNG FROZEN SECTION	LNG VASCULAR INVASION	LNG LYMPHATICS INVASION	LNG PLEURA INVASION	LNG CHEST WALL INVASION	LNG OTHER INVASION	LNG HIGH MEDIASTINAL (SCOPE)	LNG UPPER PARATRACHEAL (SCOPE)	LNG PREVASC/RETROTRACH (SCOPE)	LNG LOWER PARATRACHEAL (SCOPE)	LNG SUBAORTIC (SCOPE)	LNG PARAORTIC (SCOPE)	LNG SUBCARINAL (SCOPE)	LNG PARAESOPHAGEAL (SCOPE)	LNG PULMONARY LIGAMENT (SCOPE)	GUIDANCE	LNG PERI-OPERATIVE BLOOD REP	LNG PERI-OPERATIVE DEATH	LNG BOOST DOSE (cGy)	CHEMOTHERAPEUTIC AGENT #1	CHEMOTHERAPEUTIC AGENT #2	CHEMOTHERAPEUTIC AGENT #3	CHEMOTHERAPEUTIC AGENT #4	CHEMOTHERAPEUTIC AGENT #5	LNG CHEMOTHERAPEUTIC TOXICITY	LNG CHEMOTHERAPY/SURG SEQUENCE	LNG COMPLICATION #1	LNG COMPLICATION #2	LNG COMPLICATION #3	LNG COMPLICATION #4	LNG COMPLICATION #5	LNG TREATMENT COMPLICATION Y/N	LNG CASE ABSTRACTOR INITIALS	LNG DATE CASE WAS ABSTRACTED	LNG PROXIMAL MARGIN	LNG DISTAL MARGIN	PALPABILITY OF PRIMARY	LNG HCT VAL BEFORE TRANSFUSION	FIRST DETECTED BY	APPROACH FOR BIOPSY OF PRIMARY	BIOPSY OF OTHER THAN PRIMARY	CENSUS TRACT	OTHER CANCER	CANCER #1	CANCER #2	CANCER #3	CANCER #4	LYMPH-VASCULAR INVASION (L)	SYSTEMIC/SURGERY SEQUENCE	FOLLOW-UP HISTORY	GAS PRIOR EXPOSURE TO RAD	GAS ALCOHOL COMSUMPTION	GAS MENOPAUSAL STATUS/HOR TX	GAS H2 BLOCKER/PROTON PUMP	GAS FAMILY HIST OF GASTRIC CA	GAS H-PYLORI INFECTION	GAS DUODENAL ULCER	GAS GASTRIC ULCER	GAS HEARTBURN (BENIGN COND)	GAS PERNICIOUS ANEMIA	VENOUS INVASION (V)	GAS POLYPS OF STOMACH	GAS POLYPOSIS OF BOWEL	GAS BARRET'S ESOPHAGUS	GAS ATROPHIC GASTRITIS	GAS GASTRIC METAPLASIA	GAS ANTIBIOTICS	GAS PROTON PUMP INHIBITORS	GAS H2 BLOCKERS	GAS BISMUTH COMPOUNDS	GAS PRIOR INTRA-ABDOMINAL SURG	DATE SYSTEMIC THERAPY STARTED	GAS YEAR OF GASTRIC RESECTION	GAS PERFORMANCE STATUS AT DX	GAS HEARTBURN (SYMPTOMS)	GAS FEVER/NIGHT SWEATS	GAS ACUTE HEMATEMESIS	GAS TRANSFUSIONS FOR BLD LOSS	GAS MELENA	GAS PAIN	GAS EARLY SATIETY	GAS CT SCAN OF ABDOMEN	HEMA TRANS/ENDOCRINE PROC	HEMA TRANS/ENDOCRINE PROC DATE	HEMA TRANS/ENDOCRINE PROC @FAC	HEMA TRANS/ENDOCRINE PR@FAC DT	GAS CT SCAN OF CHEST	GAS CT PELVIS	GAS CHEST X-RAY	GAS GALLIUM SCAN	GAS BIPEDAL LYMPHANGIOGRAM	GAS MRI	GAS PET SCAN	GAS LAPAROSCOPY	GAS EUS	GAS PERITONEAL LAVAGE	PAIN ASSESSMENT	GAS LDH (IU/L)	GAS CEA (ng/ml)	GAS CA125 (U/ml)	GAS BETA2 MICROGLOBULIN	GAS URINARY 5-HIAA (mg/24hr)	GAS CLINICAL/VISUAL EXAM	GAS BIOPSY	GAS GASTRO-ESOPHAGEAL JUNCTION	GAS STOMACH	GAS LIVER	GAS EXTRA-ABDOMINAL	GAS LYMPH NODES	GAS PERITONEUM	GAS DATE OF FIRST TISSUE DX	GAS LAUREN'S CLASSIFICATION	DATE OF FIRST CONTACT	GAS GOSEKI'S CLASSIFICATION	GAS GASTRIN	GAS 5-HIAA	GAS CEA	GAS CA125	GAS OTHER MOLECULAR MARKER	GAS MITOTIC RATE	GAS TUMOR NECROSIS	GAS FLOW CYTOMETRY/FRESH TISS	GAS IMMUNOHISTOCHEM/FROZEN TIS	GAS IMMUNOHISTOCHEM/PARAFFIN	GAS MOLECULAR GENETICS	GAS POLYMERASE CHAIN REACTION	GAS SOUTHERN BLOT TECHNIQUE	GAS ANN ARBOR STAGING	GAS ADHERENCE OF RESECTED PRIM	GAS MARGIN STAT OF RESECT PRIM	GAS PROXIMAL MARGIN	GAS DISTAL MARGIN	GAS SPLEEN	GAS TRANSVERSE COLON	GAS DIAPHRAGM	GAS PANCREAS	GAS ABDOMINAL WALL	GAS ADRENAL GLAND	GAS KIDNEY	GAS SMALL INTESTINE	GAS RETROPERITONEUM	DRE DATE	GAS PERIGASTRIC LYMPH NODES	GAS COMMON HEPATIC LYMPH NODES	GAS CELIAC LYMPH NODES	GAS SPLENIC LYMPH NODES	GAS OTHER INTRA-ABDOMINAL NDES	GAS GROSSLY INVOLVED REG LN	GAS HCT VAL BEFORE TRANSFUSION	GAS TOTAL OPERATIVE BLOOD REPL	GAS INTRA/PERI-OPERATIVE DEATH	GAS ANASTOMATIC LEAK	GAS STUMP LEAK	GAS BLEEDING	GAS WOUND INFECTION	GAS SEPSIS	GAS PANCREATITIS	GAS DEAD BOWEL	GAS OTHER COMPLICATIONS	GAS DATE OF SURGICAL DISCHARGE	GAS INTRA-OPERATIVE RADIATION	GAS CONCURRENT CHEMOTHERAPY	GAS INTRAPERITONEAL CMX	ELAPSED DAYS TO COMPLETION	ELAPSED MONTHS TO COMPLETION	GAS ADMIN OF INTERFERON	GAS CO-MORBID CONDITION 1	GAS CO-MORBID CONDITION 2	GAS CO-MORBID CONDITION 3	GAS CO-MORBID CONDITION 4	GAS CO-MORBID CONDITION 5	GAS CO-MORBID CONDITION 6	GAS DURATION OF TOBACCO USE	GAS PERSONAL HIST OTH MALIG	GAS WEIGHT LOSS	GAS BOOST DOSE (cGy)	GAS CHEMOTHERAPEUTIC AGENT #1	GAS CHEMOTHERAPEUTIC AGENT #2	GAS CHEMOTHERAPEUTIC AGENT #3	GAS CHEMOTHERAPEUTIC TOXICITY	GAS CHEMOTHERAPY/SURG SEQUENCE	GAS COMPLICATION #1	GAS COMPLICATION #2	GAS COMPLICATION #3	GAS COMPLICATION #4	GAS COMPLICATION #5	AMBIGUOUS TERMINOLOGY DX	STATE AT DX	DERIVED AJCC-6 T	DERIVED AJCC-7 T	DERIVED AJCC-6 T DESCRIPTOR	DERIVED AJCC-7 T DESCRIPTOR	DERIVED AJCC-6 N	DERIVED AJCC-7 N	DERIVED AJCC-6 N DESCRIPTOR	DERIVED AJCC-7 N DESCRIPTOR	DERIVED AJCC-6 M	DERIVED AJCC-7 M	DERIVED AJCC-6 M DESCRIPTOR	DERIVED AJCC-7 M DESCRIPTOR	DERIVED AJCC-6 STAGE GROUP	DERIVED AJCC-7 STAGE GROUP	DERIVED SS1977	DERIVED SS2000	CS VERSION DERIVED	CS VERSION INPUT ORIGINAL	SUSPENSE DATE	DATE FIRST SURGICAL PROCEDURE	DATE START OF WORKUP ORDERED	DATE WORKUP STARTED	BLOOD IN SPUTUM PER PT	DATE OF BLOOD IN SPUTUM PER PT	CHEST X-RAY	DATE OF CHEST X-RAY	CT SCAN	DATE OF CT SCAN	SUMMARY STAGE 2018	BRONCHOSCOPY	DATE OF BRONCHOSCOPY	EOD PRIMARY TUMOR	EOD REGIONAL NODES	EOD METS	MEDIASTINOSCOPY	DATE OF MEDIASTINOSCOPY	PET SCAN	DATE OF PET SCAN	PRIMARY PAYER AT DX	CHANGE IN BOWEL HABITS PER PT	DATE OF CHANGE IN BOWEL HABITS	FECAL OCCULT BLOOD TEST (FOBT)	DATE OF FOBT	BARIUM ENEMA	DATE OF BARIUM ENEMA	SIGMOIDOSCOPY	DATE OF SIGMOIDOSCOPY	CT OF ABDOMEN/PELVIS	DATE OF CT OF ABDOMEN/PELVIS	COLONOSCOPY	DATE OF COLONOSCOPY	DYSPNEA	DATE OF DYSPNEA	INCREASED COUGH	DATE OF INCREASED COUGH	FEVER	DATE OF FEVER	NIGHT SWEATS	DATE OF NIGHT SWEATS	STAGED BY (CLINICAL STAGE)	WEIGHT LOSS PER PT	ULCERATIVE COLITIS (UC)	SPORADIC POLYPS	DATE OF CONCLUSIVE DX	MULT TUM RPT AS ONE PRIM	DATE OF MULTIPLE TUMORS	MULTIPLICITY COUNTER	EDITS CHECKSUM	CHECKSUM VERSION	DATE CASE LAST CHANGED	CASE LAST CHANGED BY	PRIMARY SURGEON	FOLLOWING PHYSICIAN	MANAGING PHYSICIAN	PHYSICIAN #3	PHYSICIAN #4	PRIMARY SITE	PRIMARY SITE CODE	DATE LAST CONTACT	DIVISION	SURVIVAL DAYS	SURVIVAL MONTHS	SURVIVAL (YEARS)	WEEKS of FOLLOW-UP	OVER-RIDE AGE/SITE/MORPH	OVER-RIDE SEQNO/DXCONF	OVER-RIDE SITE/LAT/SEQNO	OVER-RIDE SURG/DXCONF	OVER-RIDE SITE/TYPE	CASEFINDING SOURCE	INFRA/SUPRA	IRIS/CILIARY BODY	UPPER/LOWER	OVER-RIDE HISTOLOGY	OVER-RIDE REPORT SOURCE	OVER-RIDE ILL-DEFINE SITE	OVER-RIDE LEUK,LYMPHOMA	OVER-RIDE SITE/BEHAVIOR	OVER-RIDE SITE/EOD/DX DT	OVER-RIDE SITE/LAT/EOD	OVER-RIDE SITE/LAT/MORPH	OVER-RIDE SS/NODESPOS	OVER-RIDE SS/TNM-N	HISTOLOGY (ICD-O-2)	ICDO HISTOLOGY-CODE	PAPILLARY/FOLLICULAR	HISTOLOGY (ICD-O-3)	BEHAVIOR CODE	OVER-RIDE SS/TNM-M	OVER-RIDE SS/DISMET1	OVER-RIDE ACSN/CLASS/SEQ	OVER-RIDE HOSPSEQ/DXCONF	OVER-RIDE COC-SITE/TYPE	OVER-RIDE HOSPSEQ/SITE	OVER-RIDE SITE/TNM-STGGRP	PERFORMANCE STATUS AT DX	TREATMENT GUIDELINE #1	TREATMENT GUIDELINE #2	RECONSTRUCTION/RESTORATION	TREATMENT GUIDELINE #3	TREATMENT GUIDELINE LOCATION	TREATMENT GUIDELINE DOC DATE	INPATIENT STATUS	RX HOSP--SURG APP 2010	TREATMENT STATUS	DATE CASE INITIATED	FEE BASIS	FEE BASIS LOCATION	OUTSIDE SLIDES REVIEWED	MITOTIC RATE	GRADE/DIFFERENTIATION	GRADE PATH SYSTEM	GRADE PATH VALUE	GRADE CLINICAL	GRADE PATHOLOGICAL	GRADE POST THERAPY PATH (YP)	GRADE POST THERAPY CLIN (YC)	CS SCHEMA DISCRIMINATOR	TNM CLIN DESCRIPTOR	TNM PATH DESCRIPTOR	INITIATED BY	NEOADJUVANT THERAPY (PRE-2021)	NEOADJUVANT THERAPY	NEOADJUVANT THERAPY-CLIN RESP	NEOADJUVANT THERAPY-TX EFFECT	CS REVIEW REQUIRED	NOTE TITLE	NOTE DATE	TNM FORM ASSIGNED	TUMOR MARKER 1	TUMOR MARKER 2	TUMOR MARKER 3	GLEASON SCORE PATH - OBSOLETE	NSLC STAGE 1-3 PATH LN STAGING	REASON FOR NO LN BIOPSY	DATE OF SURGERY CONSULT	INTENT OF SURGERY	DATE ONCOLOGY CONSULT ORDERED	DATE ONCOLOGY CONSULT DONE	CHEMOTHERAPY RECOMMENDED	INTENT OF CHEMOTHERAPY	TYPE OF CHEMOTHERAPY	DIAGNOSTIC CONFIRMATION	REASON RADIATION STOPPED	DOC FOR NO PLAT-BASED CHEMO	MULTIMODALITY RADIATION TYPE	REASON HORMONE THERAPY STOPPED	DATE HOSPICE CONSULT INITIATED	DATE HOSPICE CONSULT COMPLETED	DATE HOSPICE CARE INITIATED	EGFR MUTATION TESTING	EGFR MUTATION 1	EGFR MUTATION 2	HISTO-MORPHOLOGY	PREOP OBSTRUCTING LESION	ONCOLOGY REFERRAL	DATE CHEMOTHERAPY RECOMMENDED	ANTI-EGFR MoAB THERAPY	PERIRECTAL LN INVOLVEMENT	RISK OF RECURRENCE	ANDROGEN DEPRIVATION THERAPY	DATE ADT INITIATED	NON-ADT CHEMOTHERAPY	CLINICAL TRIALS DISCUSSION	LATERALITY	CLIN TNM DOCUMENTATION PRE-TX	CL TNM DOCUMENTATION LOCATION	CL TNM DOCUMENTATION DATE	TX GUIDELINES DISCUSSION	VACCR EXTRACT INDICATOR	CS FIELD NEEDING REVIEW	UDF1	UDF2	UDF3	UDF4	UDF5	UDF6	UDF7	UDF8	UDF9	UDF10	TEXT-STAGING	TEXT-SITE SPECIFIC DATA ITEMS	TEXT-COVID-19	TOBACCO USE SMOKING STATUS	TEXT-HIV, SCA, DRUG & ETOH	TUMOR SIZE/EXT EVAL (CS)	TUMOR SIZE (CS)	TUMOR SIZE SUMMARY	TUMOR SIZE CLINICAL	TUMOR SIZE PATHOLOGIC	EXTENSION LIST USED	DATE DX	DIAGNOSIS EPISODE CARE	YEAR DX	EXTENSION	PATHOLOGIC EXTENSION	EXTENSION (CS)	PERIPHERAL BLOOD INVOLVEMENT	LYMPH NODE LIST USED	PATIENT REFERRED FOR TREATMENT	CLASS OF CASE CONVERSION FLAG	STATE AT DX CONVERSION FLAG	LENGTH OF STAY	HISTORY OF CERVIX CA (PT)	HISTORY OF COLON CA (PT)	HISTORY OF BLADDER CA (PT)	HISTORY OF HEAD & NECK CA (PT)	HISTORY OF KIDNEY CA (PT)	HISTORY OF PROSTATE CA (PT)	HISTORY OF OTHER CA (PT)	HISTORY OF BLADDER CA (FAM)	LYMPH NODES	LYMPH NODES (CS)	HISTORY OF COLON CA (FAM)	HISTORY OF LUNG CA (FAM)	HISTORY OF PROSTATE CA (FAM)	HISTORY OF OTHER CA (FAM)	SMOKING HISTORY	DURATION OF SMOKING HISTORY	DURATION OF SMOKE FREE HISTORY	GROSS HEMATURIA	MICROSCOPIC HEMATURIA	URINARY FREQUENCY	REGIONAL LYMPH NODES POSITIVE	LYMPH NODES EVAL (CS)	BLADDER IRRITABILITY	DYSURIA	OTHER CLINICAL DETECTIONS	ONSET OF SYMPTOMS	DURATION OF GROSS HEMATURIA	DURATION OF DYSURIA	BIMANAUL EXAM OF BLADDER	CYSTOSCOPY WITH BIOPSY	CYSTOSCOPY WITHOUT BIOPSY	FLOW CYTOMETRY	REGIONAL LYMPH NODES EXAMINED	#NODES EXAMINED	INTRAVENOUS PYELOGRAM (BLA)	URINE CYTOLOGY	URINALYSIS	OTHER DIAGNOSTIC PROCEDURES	SPECIALTY MAKING DIAGNOSIS	ABDOMINAL ULTRASOUND	BONE IMAGING	CHEST X-RAY (BLADDER)	CT CHEST/LUNG	CT ABDOMEN/PELVIS	SITE OF DISTANT METASTASIS #1	SITE OF DISTANT METASTASIS #2	SITE OF DISTANT METASTASIS #3	METS AT DX (CS)	METS AT DX-BONE	METS AT DX-BRAIN	METS AT DX-LIVER	METS AT DX-LUNG	METS AT DX-DISTANT LN	METS AT DX-OTHER	METS EVAL (CS)	CT OTHER	MRI PELVIS/ABDOMEN	MRI OTHER	OTHER STAGING PROCEDURES	PRESENCE OF HYDRONEPHROSIS	PRESENCE OF MULTIPLE TUMORS	PROTOCOL ELIGIBILITY STATUS	MANAGING PHYSICIAN (PRIMARY)	MANAGING PHYSICIAN (SECONDARY)	TUMOR RESECTION DURING TURB	SEER SUMMARY STAGE 2000	SEER SUMMARY STAGE ABBREVIATED	TYPE OF URINARY DIVERSION	PELVIC LYMPH NODE DISSECT (BL)	BLEEDING REQUIRING TRANSFUSION	DEEP VENOUS THROMBOSIS	MYOCARDIAL INFARCTION (MI)	PELVIC ABSCESS	PNEUMONIA REQ ANTIBIOTICS	POST-OPERATIVE DEATH	PULMONARY EMBOLISM/THROMBOSIS	REOPERATION	AJCC STAGING BASIS	OTHER SURGICAL COMPLICATIONS	DATE RADIATION ENDED	TOTAL RAD (cGy/rad) DOSE	REGIONAL TREATMENT MODALITY	BOOST TREATMENT MODALITY	URINARY INCONTINENCE	HEMATURIA	RADIATION BOWEL INJURY	DATE CHEMOTHERAPY ENDED	ROUTE CHEMOTHERAPY ADMIN	ADRIAMYCIN	TNM CLINICAL	CLINICAL T	CLINICAL N	CLINICAL M	AUTOMATIC STAGING OVERRIDDEN	CARBOPLATINUM	SEER SSF1-HPV STATUS	CYCLOPHOSPHAMIDE	5-FLUOROURACIL	GALLIUM NITRATE	IFOSFAMIDE	METHOTREXATE	TAXOL	THIOTEPA	VINBLASTINE	STAGE GROUP CLINICAL	GP-I AJCC SUMMARY STAGE	GP-II AJCC SUMMARY STAGE	GP-III AJCC SUMMARY STAGE	GP-IV AJCC SUMMARY STAGE	STAGE GROUPING-AJCC	OTHER CHEMOTHERAPEUTIC AGENTS	SCHEMA ID	SCHEMA ID DESCRIPTION	CHROMOSOME 1P: (LOH)	CHROMOSOME 19Q: (LOH)	ADENOID CYSTIC BASALOID PTTRN	ADENOPATHY	AFP POST-ORCHIECTOMY LAB VAL	AFP POST-ORCHIECTOMY RANGE	AFP PRE-ORCHIECTOMY LAB VALUE	AFP PRE-ORCHIECTOMY RANGE	AFP PRETREATMENT INTERPRET	INDICATION FOR ADMIN OF AGENTS	AFP PRETREATMENT LAB VALUE	ANEMIA	B SYMPTOMS	BILIRUBIN PRE TOTAL LAB VALUE	BILIRUBIN PRETREATMENT UNIT	BONE INVASION	BRAIN MOLECULAR MARKERS	BRESLOW TUMOR THICKNESS	CA-125 PRETREATMENT INTER	CEA PRETREATMENT INTER	REASON CHEMOTHERAPY STOPPED	CEA PRETREATMENT LAB VALUE	CHROMOSOME 3 STATUS	CHROMOSOME 8Q STATUS	CIRCUMFERENTIAL RESECT MARGIN	CREATININE PRETREAT LAB VALUE	CREATININE PRETREAT UNIT	ER PERCENT POSITIVE	ER SUMMARY	ER ALLRED SCORE	ESOPHAGUS EGJ TUMOR EPICENTER	BCG	ENE CLIN (NON-HEAD AND NECK)	ENE HEAD AND NECK CLINICAL	ENE HEAD AND NECK PATHOLOGICAL	ENE PATH (NON-HEAD AND NECK)	EXTRAVASCULAR MATRIX PATTERNS	FIBROSIS SCORE	FIGO STAGE	GESTATIONAL TROPHOBLASTIC	GLEASON PATTERNS CLINICAL	GLEASON PATTERNS PATHOLOGICAL	INTERFERON	GLEASON SCORE CLINICAL	GLEASON SCORE PATHOLOGICAL	GLEASON TERTIARY PATTERN	HCG POST-ORCHIECTOMY LAB VALUE	HCG POST-ORCHIECTOMY RANGE	HCG PRE-ORCHIECTOMY LAB VALUE	HCG PRE-ORCHIECTOMY RANGE	INTERLEUKIN-2	HER2 IHC SUMMARY	HER2 ISH DUAL PROBE COPY NUM	HER2 ISH DUAL PROBE RATIO	HER2 ISH SINGLE PROBE COPY NUM	HER2 ISH SUMMARY	HER2 OVERALL SUMMARY	HERITABLE TRAIT	HIGH RISK CYTOGENETICS	HIGH RISK HISTOLOGIC FEATURES	HIV STATUS	OTHER TYPE OF IMMUNOTHERAPY	INR PROTHROMBIN TIME	IPSILATERANL ADRENAL GLAND INV	JAK2	KI-67	INVASION BEYOND CAPSULE	KIT GENE IMMUNOHISTOCHEMISTRY	KRAS	LDH POST-ORCHIECTOMY RANGE	LDH PRE-ORCHIECTOMY RANGE	LDH LEVEL	TYPE OF 1ST RECURRENCE/BLADDER	LDH UPPER LIMITS OF NORMAL	LN ASSESS METH FEMORAL-INGUIN	LN ASSESS METHOD PARA-AORTIC	LN ASSESSMENT METHOD PELVIC	LN DISTANT ASSESSMENT METHOD	LN DISTANT MEDIASTINAL,SCALENE	LN HEAD & NECK LEVELS I-III	LN HEAD & NECK LEVELS IV-V	LN HEAD & NECK LEVELS VI-VII	LN HEAD AND NECK OTHER	LN ISOLATED TUMOR CELLS (ITC)	LN LATERALITY	LN POSITIVE AXILLARY LVL I-II	LN SIZE	LN STATUS FEM-ING,PAR-AOR,PLV	LYMPHOCYTOSIS	MAJOR VEIN INVOLVEMENT	MEASURED BASAL DIAMETER	MEASURED THICKNESS	METHYLATION OF MGMT	MICROSATELLITE INSTABILITY	MICROVASCULAR DENSITY	MITOTIC COUNT UVEAL MELANOMA	MITOTIC RATE MELANOMA	MULTIGENE SIGNATURE METHOD	MULTIGENE SIGNATURE RESULTS	NCCN IPI	NUMBER OF CORES EXAMINED	NUMBER OF CORES POSITIVE	NUM OF EXAMINED PARA-AORTIC	OTHER STAGING SYSTEM	NUM OF EXAMINED PELVIC NODES	NUM OF POS PARA-AORTIC NODES	NUM OF POSITIVE PELVIC NODES	ONCOTYPE DX RECUR SCORE-DCIS	ONCOTYPE DX REC SCORE-INVASIVE	ONCOTYPE DX RISK LEVEL-DCIS	ONCOTYPE DX RISK LEVEL-INVAS	ORGANOMEGALY	PERCENT NECROSIS PST NEOADJVNT	PERINEURAL INVASION 2018	PERIPHERAL BLOOD INVOLV 2018	PERITONEAL CYTOLOGY	PLEURAL EFFUSION	PR PERCENT POSITIVE	PR SUMMARY	PR ALLRED SCORE	PRIMARY SCLEROSING CHOLANGITIS	PROFOUND IMMUNE SUPPRESSION	PROSTATE PATHOLOGICAL EXT	PSA LAB VALUE	RESIDUAL TUM VOL PST CYTO	RESPONSE TO NEOADJUVANT THERA	S CATEGORY CLINICAL	S CATEGORY PATHOLOGICAL	SARCOMATOID FEATURES	SCHEMA DISCRIMINATOR 1	SCHEMA DISCRIMINATOR 2	SCHEMA DISCRIMINATOR 3	SEPARATE TUMOR NODULES	SERUM ALBUMIN PRETREAT VALUE	SERUM BETA-2 MICROGLOBULIN	LDH LAB VALUE	THROMBOCYTOPENIA	TUMOR DEPOSITS	TUMOR GROWTH PATTERN	ULCERATION 2018	VISCERAL PARIETAL PLEURAL INV	ALK REARRANGEMENT	EGFR MUTATIONAL ANALYSIS	BRAF MUTATIONAL ANALYSIS	NRAS MUTATIONAL ANALYSIS	CA 19-9 PRETX LAB VALUE	NCDB-SARSCOV2-TEST	NCDB-SARSCOV2-POSITIVE	NCDB-SARSCOV2-POSITIVE DATE	NCDB-COVID19-TX IMPACT	MACROSCOPIC EVAL OF MESORECTUM	DERIVED RAI STAGE	P16	LN STATUS PELVIC	LN STATUS PARA-AORTIC	LN STATUS FEMORAL-INGUINAL	HISTOLOGIC SUBTYPE	CLINICAL MARGIN WIDTH	BRAIN PRIMARY TUMOR LOCATION	AGE AT DX	DX AGE-GP	STAGE GROUP BEST	TNM BEST	STAGED BY	HISTORY OF THYROID CA (FAM)	HISTORY OF LYMPHOMA (PT)	HISTORY OF CHILDHOOD MALIG	PRIOR EXPOSURE TO RADIATION	HISTORY OF GOITER (PT)	HISTORY OF GOITER (FAM)	HISTORY OF GRAVES DISEASE (PT)	HISTORY OF THYROIDITIS (PT)	DYSPHAGIA	HOARSENESS OR VOICE CHANGE	ASSOCIATED WITH HIV	NECK NODAL MASS	PAIN, BONE	PAIN, NECK	PATHOLOGIC FRACTURE	STRIDOR/DIFFICULTY BREATHING	THYROID MASS	WEIGHT LOSS	OTHER SIGNS/SYMPTOMS	BONE SCAN (THYROID)	CHEST X-RAY (THYROID)	TREATMENT ABBREVIATED	CT SCAN OF NECK (THYROID)	CT SCAN OF CHEST	INCISIONAL BIOPSY OF THYROID	LARYNGOSCOPY	NECK X-RAY (AP & LATERAL)	NEEDLE ASPIRATION OF NECK NODE	NEEDLE ASPIRATION OF THYROID	MRI OF NECK	THYROID SCAN	ULTRASOUND OF THYROID	TREATMENT	OTHER DIAGNOSTIC/SURGICAL TEST	BLOOD VESSEL INVASION	EXTRA-THYROIDAL EXTENSION	MULTIFOCAL	LOCATION OF POSITIVE NODES	DATE MOST DEFINITIVE SURG DIS	AIRWAY PROBLEM	BLEEDING/HEMATOMA	HYPOCALCEMIA	RECURRENT NERVE INJURY	TNM FORM COMPLETED	SSF1	SSF10	SSF11	SSF12	SSF13	SSF14	SSF15	SSF16	SSF17	SSF18	SSF19	SSF2	SSF20	SSF21	SSF22	SSF23	SSF24	SSF25	SSF3	SSF4	SSF5	SSF6	SSF7	SSF8	SSF9	WOUND INFECTION	POSTOPERATIVE DEATH	REGIONAL DOSE: cGy	BOOST DOSE: cGy	INITIAL DOSE OF RADIOIODINE	SECOND DOSE OF RADIOIODINE	ADJUVANT CHEMOTHERAPY (THY)	PERFORMANCE STATUS	CAP PROTOCOL REVIEW	CAP TEXT	OTHER PRIMARY SITES	DATE 1ST CRS RX COC	FIRST TREATMENT DT-DATE DX	DATE INITIAL RX SEER	DX FACILITY	MOST DEFINITIVE SURG DATE	SURGERY HOSPITAL	SURGERY OF PRIMARY @FAC (R)	MOST DEFINITIVE SURG @FAC DATE	HISTORY OF SOFT TIS SARC (FAM)	AJCC ID	AJCC TNM CLIN T	AJCC TNM CLIN N	AJCC TNM CLIN M	AJCC TNM CLIN STAGE GROUP	HISTORY OF ANY CANCER (PT)	AJCC TNM PATH T	AJCC TNM PATH N	AJCC TNM PATH M	AJCC TNM PATH STAGE GROUP	ANGIOGRAM OF PRIMARY	AJCC TNM POST THER (yp) T	AJCC TNM POST THER (yp) N	AJCC TNM POST THER (yp) M	AJCC TNM POST THER (yp) SG	AJCC TNM POST THER (yc) T	AJCC TNM POST THER (yc) N	AJCC TNM POST THER (yc) M	AJCC TNM POST THER (yc) SG	BONE MARROW ASPIRATE OR BIOPSY	AJCC TNM CLIN T SUFFIX	AJCC TNM PATH T SUFFIX	AJCC TNM POST THER (yp) T SFX	AJCC TNM POST THER (yc) T SFX	AJCC TNM CLIN N SUFFIX	AJCC TNM PATH N SUFFIX	AJCC TNM POST THER (yp) N SFX	AJCC TNM POST THER (yc) N SFX	BONE SCAN (SOFT TIS SARCOMA)	CHEST X-RAY (STS/NHL)	CT SCAN OF CHEST (STS)	CT SCAN OF PRIMARY	LIVER FUNCTION STUDIES (STS)	LYMPHANGIOGRAM	DATE RADIATION STARTED	RADIATION HOSPITAL	RADIATION	RADIATION/SURGERY SEQUENCE	RADIATION @FACILITY	RADIATION @FACILITY DATE	MRI OF PRIMARY	MRI OF OTHER	SKELETAL X-RAY	SONOGRAM	CYTOGENETICS	ELECTRON MICROSCOPY	IMMUNOHISTOCHEMISTRY	IN SITU HYBRIDIZATION	OUTSIDE CONFIRMATION REQUESTED	SUBSITE	RADIATION THERAPY TO CNS DATE	RADIATION THERAPY TO CNS HOSP	RADIATION THERAPY TO CNS	TYPE OF ADDITIONAL CODING SYS	VALUE OF ADDITIONAL CODING SYS	PATHOLOGIC SIZE OF TUMOR	DEPTH OF TUMOR	CONSULTATIONS (MED ONCOLOGIST)	CONSULTATIONS (RAD ONCOLOGIST)	TREATING SURGEON	ASA CLASS	FINE NEEDLE ASPIRATION	CORE NEEDLE BIOPSY	CHEMOTHERAPY DATE	CHEMOTHERAPY HOSPITAL	CHEMOTHERAPY	CHEMOTHERAPY @FAC	CHEMOTHERAPY @FAC DATE	INCISIONAL BIOPSY (STS PCE)	EXCISIONAL BIOPSY	EXTERNAL BEAM RADIATION	EXTERNAL BEAM RAD FRACTIONS	EXTERNAL BEAM RADIATION ENERGY	INTRAOPERATIVE RADIATION	INTRAOPERATIVE RADIATION DOSE	INTRAOPERATIVE RADIATION ENER	BRACHYTHERAPY	BRACHYTHERAPY DAYS	HORMONE THERAPY DATE	HORMONE THERAPY HOSPITAL	HORMONE THERAPY	HORMONE THERAPY @FAC	HORMONE THERAPY @FAC DATE	BRACHYTHERAPY RADIATION DOSE	DATE BRACHYTHERAPY STARTED	DATE BRACHYTHERAPY ENDED	CYTOXAN	DTIC	DOXORUBICIN (STS)	ETOPOSIDE	CISPLATIN METHOD OF DELIVERY	CYTOXAN METHOD OF DELIVERY	DTIC METHOD OF DELIVERY	IMMUNOTHERAPY DATE	IMMUNOTHERAPY HOSPITAL	IMMUNOTHERAPY	IMMUNOTHERAPY @FAC	IMMUNOTHERAPY @FAC DATE	DOXORUBICIN METHOD OF DELIVERY	PHASE 1 DOSE PER FRACTION	PHASE 1 RAD EXT BEAM PLAN TECH	PHASE 1 NUMBER OF FRACTIONS	PHASE 1 RAD TREATMENT VOLUME	PHASE 1 RAD TO DRAINING LN	PHASE 1 RAD TREATMENT MODALITY	PHASE 1 TOTAL DOSE	ETOPOSIDE METHOD OF DELIVERY	PHASE 2 DOSE PER FRACTION	PHASE 2 RAD EXT BEAM PLAN TECH	PHASE 2 NUMBER OF FRACTIONS	PHASE 2 RAD TREATMENT VOLUME	PHASE 2 RAD TO DRAINING LN	PHASE 2 RAD TREATMENT MODALITY	PHASE 2 TOTAL DOSE	IFOSFAMIDE METHOD OF DELIVERY	PHASE 3 DOSE PER FRACTION	PHASE 3 RAD EXT BEAM PLAN TECH	PHASE 3 NUMBER OF FRACTIONS	PHASE 3 RAD TREATMENT VOLUME	PHASE 3 RAD TO DRAINING LN	PHASE 3 RAD TREATMENT MODALITY	PHASE 3 TOTAL DOSE	CISPLATIN LOCATION	CYTOXAN LOCATION	DTIC LOCATION	DOXORUBICIN LOCATION	ETOPOSIDE LOCATION	IFOSFAMIDE LOCATION	COLONY STIMULATING FACTORS	NUMBER OF TXS TO THIS VOLUME	PROTOCOL PARTICIPATION	OTHER PROTOCOL	REFERRED TO REHAB SERVICES	PHYSICAL THERAPY/REHABILTATION	TRANSFERRED TO REHABILITATION	NUMBER OF HOSPITALIZATIONS	TOTAL LENGTH OF STAYS	DATE EXT BEAM RAD STARTED	OTHER TREATMENT START DATE	OTHER TREATMENT HOSPITAL	OTHER TREATMENT	OTHER TREATMENT @FAC	OTHER TREATMENT @FACILITY DATE	REASON NO SURGERY OF PRIMARY	SURGICAL DX/STAGING PROC	SURGERY OF PRIMARY (R)	SURGICAL DX/STAGING PROC DATE	SURG DX/STAGING PROC @FAC	SURG DX/STAGING PROC @FAC DATE	RX SUMM--SURG PRIMSITE 03-2022	RX HOSP--SURG PRIMSITE 03-2022	RX HOSP--SURG PRIM SITE 2023	RX SUMM--SURG PRIM SITE 2023	SURGICAL MARGINS	FACILITY REFERRED FROM	SUBSEQUENT COURSE OF TREATMENT	CLINICAL DX WITH BONE LESION	CLINICAL DX BY RECTAL EXAM	CYTOLOGY	INCIDENTAL FINDING IN TURP	NEEDLE ASPIRATION BIOPSY	NEEDLE BIOPSY, NOS	PERINEAL BIOPSY	TRANSRECTAL BIOPSY	TRUS	TRANSURETHRAL RESECTION	PID#	OTHER METHOD OF DX (PROSTATE)	BONE MARROW ASPIRATION	BONE SCAN (PROSTATE)	BONE X-RAY	CHEST X-RAY (PROSTATE)	CT SCAN OF PRIMARY SITE	INTRAVENOUS PYELOGRAM (PRO)	LIVER SCAN	MRI (PRO)	PELVIC LYMPH NODE DISSECT (PR)	QA SELECTED	PROSTATIC ACID PHOSPHATASE	PROSTATE SPECIFIC ANTIGEN	OTHER DIAGNOSTIC INFORMATION	GLEASON SCORE CLIN - OBSOLETE	PREDOMINANT PATTERN (02-40)	LESSER PATTERN (02-40)	GLEASON'S SCORE (50-70)	PREDOMINANT PATTERN (50-70)	LESSER PATTERN (50-70)	RESEARCH PROTOCOL	RAD THERAPY PLANNED/GIVEN	INTERSTITIAL RAD PLANNED/GIVEN	IODINE 125	GOLD 198	PALLADIUM 103	QA REVIEW	IRIDIUM 192	OTHER INTERSTITIAL, NOS	EXTERNAL RAD PLANNED/GIVEN	PROSTATE REGION ONLY	PROSTATE AND PELVIC NODES	PROSTATE & PELVIC PARA-AORTIC	DISTANT METASTATIC SITES	OTHER EXTERNAL SITES, NOS	TOTAL RAD DOSE (PROSTATE)	TOTAL RAD DOSE (PELVIC NODES)	QA DATE	QA REVIEWER	QA FINDINGS	TOTAL RAD DOSE (PARA-AORTIC)	RESEARCH PROTOCOL (RADIATION)	HORMONE THERAPY PLANNED/GIVEN	ESTROGENS	ANTIANDROGENS	PROGESTATIONAL AGENTS	LUTEINIZING HORMONES	ORCHIECTOMY	OTHER EXOGENOUS HORMONE AGENTS	BACKACHE (1ST RECURRENCE)	PHYSICIAN'S STAGE	BONE SCAN (1ST RECURRENCE)	LETHARGY	RECTAL EXAM (1ST RECURRENCE)	TUMOR MARKER (1ST RECURRENCE)	WEIGHT LOSS (1ST RECURRENCE)	OTHER METHODS (1ST RECURRENCE)	REASON FOR 2ND COURSE	FAM HIST OF PROSTATE CA (PR98)	HEMATURIA (PR98)	LOWER BACK PAIN (PR98)	PHYSICIAN STAGING	TROUBLE URINATING (PR98)	CLIN DX W/ BONE LESION (PR98)	CLIN DX BY RECTAL EXAM (PR98)	CYTOLOGY (PR98)	DIGITAL TRANSRECTAL BIO (PR98)	INCIDENTAL FIND IN TURP (PR98)	NEEDLE BIOPSY, NOS (PR98)	PERINEAL BIOPSY (PR98)	PSA METHOD OF DIAGNOSIS (PR98)	TRANSRECTAL BIOPSY (PR98)	ACOS #	TRANSURETHRAL RESECTION (PR98)	BONE MARROW ASPIRATION (PR98)	BONE SCAN (PR98)	BONE X-RAY (PR98)	CHEST X-RAY (PR98)	CT SCAN OF ABDOMEN (PR98)	CT SCAN OF PELVIS (PR98)	INTRAVENOUS PYELOGRAM (PR98)	MRI (PR98)	PELVIC LYMPH ND DISSECT (PR98)	STATE HOSPITAL #	POLYMERASE CHAIN REACT (PR98)	PROSTATIC ACID PHOSPH (PR98)	PSA DIAGNOSTIC EVAL (PR98)	ULTRASOUND OF ABDOMEN (PR98)	PSA	WATCHFUL WAITING (PR98)	LENGTH OF STAY (PR98)	LAPAROSCOPIC (PR98)	OPEN (PR98)	PERMANENT RECTAL INJURY (PR98)	MULTIPLE TUMORS	FAMILY HISTORY	DIFFUSE RETINAL INVOLVEMENT	MULTIMODALITY THERAPY (CLIN)	MULTIMODALITY THERAPY	THROMBOEMBOLISM (PR98)	URETHRAL STRICTURE (PR98)	RADIATION FACILITY	ROUTE OF INTERSTITIAL RAD	TYPE OF RADIATION ADMIN	GASTROINTESTINAL COMPLICATIONS	GASTROURINARY COMPLICATIONS	ANORECTAL COMPLICATIONS	CHRONIC COMPLICATIONS	URETHRAL/BLADDER COMPLICATIONS	DATE OF ORCHIECTOMY	FACILITY REFERRED TO	DATE OF FIRST RECURRENCE	HISTORY OF COLORECTAL CA (FAM)	STATE AT DX GEOCODE 1970/80/90	STATE AT DX GEOCODE 2010	BEHAVIOR (73-91) ICD-O-1	GRADE (73-91) ICD-O-1	RUCA 2000	RUCA 2010	URIC 2000	URIC 2010	DERIVED EOD 2018 T	DERIVED EOD 2018 N	HISTORY OF COLORECTAL CA (PT)	DERIVED EOD 2018 M	DERIVED EOD 2018 STAGE GROUP	DERIVED SUMMARY STAGE 2018	DATE REGIONAL LN DISSECTION	DATE REG LN DISSECTION FLAG	SENTINEL LYMPH NODES POSITIVE	SENTINEL LYMPH NODES EXAMINED	DATE OF SENTINEL LN BIOPSY	DATE OF SENTINEL LN BIOPSY FLG	NPCR DERIVED AJCC8 CLN STG GRP	MULTIPLE COLORECTAL PRIMARIES	NPCR DERIVED AJCC8 PTH STG GRP	NPCR DERIVED AJCC8 PT STG GRP	NPCR SPECIFIC FIELD	STATE AT DX GEOCODE 2000	NUMBER OF PHASES RAD TX	RADIATION TREATMENT DISC EARLY	TOTAL DOSE	OVER-RIDE TNM STAGE	OVER-RIDE TNM TIS	OVER-RIDE TNM 3	HISTORY OF BREAST CA (PT)	OVER-RIDE NAME/SEX	HISTOLOGY (73-91) ICD-O-1	RQRS NCDB SUBMISSION FLAG	COC ACCREDITED FLAG	VITAL STATUS RECODE	RECORD NUMBER RECODE	SEER CAUSE SPECIFIC COD	SEER OTHER COD	HISTORY OF LUNG CA (PT)	MEDICARE BENEFICIARY ID	HISTORY OF OVARIAN CA (PT)	HISTORY OF OVARIAN CARCINOMA	HISTORY OF STOMACH CA (PT)	HISTORY OF THYROID CA (PT)	HISTORY OF UTERUS CA (PT)	TYPE OF FIRST RECURRENCE	DISTANT SITE 1	DISTANT SITE 2	DISTANT SITE 3	OTHER TYPE OF FIRST RECURRENCE	PREVIOUS TAH/BSO	FAMILIAL ADENOMATOUS POLYPS	HNPCC	INFLAMMATORY BOWEL DISEASE	PRIOR POLYPS	POLYPS	DURATION OF ANEMIA	DURATION OF BOWEL OBSTRUCTION	DURATION OF BOWEL HABIT CHANGE	DURATION OF EMERGENCY PRES-OBS	SUBSEQUENT RECURRENCES	DURATION OF JAUNDICE	DURATION OF MALAISE	DURATION OF BLOOD IN STOOL	DURATION OF PAIN (ABDOMINAL)	DURATION OF PAIN (PELVIC)	DURATION OF RECTAL BLEEDING	DURATION OF OTHER	ENDOSCOPIC METHOD	RADIOGRAPHIC METHOD	SCREENING DIGITAL RECTAL EXAM	TUMOR STATUS	SCREENING PHYSICAL EXAM METHOD	OTHER INITIAL METHOD	REASON LEADING TO EVENTUAL DX	BARIUM ENEMA, DOUBLE CONTRAST	BARIUM ENEMA, SINGLE CONTRAST	BARIUM ENEMA, NOS	BIOPSY OF PRIMARY SITE	BIOPSY OF METASTATIC SITE	CT SCAN OF LIVER	CT SCAN OF PRIMARY SITE (COL)	SURGICAL APPROACH (R)	CARCINOEMBRYONIC ANTIGEN (CEA)	CHEST ROENTGENOGRAM	DIGITAL RECTAL EXAM	FLEXIBLE SIGMOIDOSCOPY	INTRAVENOUS PYELOGRAM (COL)	SERUM-LIVER FUNCTION TEST	MRI (COL)	PROCTOSCOPY (RIGID)	STOOL GUAIAC (OCCULT BLOOD)	REASON FOR NO RADIATION	ULTRASOUND, LIVER, ABDOMEN	ULTRASOUND, ENDORECTAL	TUMOR LEVEL-ENDOSCOPIC EXAM	LEVEL OF RECTAL TUMOR	PROXIMAL MARGIN OF RESECTION	DISTAL MARGIN OF RESECTION	RADIAL MARGIN OF RESECTION	DIST TO CLOSEST MUCOSAL MARGIN	DIST TO CLOSEST RADIAL MARGIN	BLOOD VESSEL OR LYMPHATIC INV	REASON FOR NO CHEMOTHERAPY	EXTRAMURAL VENOUS INVASION	PROMINENT LYMPHOID INFILTRATE	PHYS PROVIDING DEF TREATMENT	ADDITIONAL SURGICAL PROCEDURES	LAPAROSCOPY USED DURING CDS	METHOD OF ANASTOMOSIS	CM FROM ANASTOMOSIS TO DENTATE	COLOSTOMY	OOPHORECTOMY	PATHOLOGICAL STATUS	REASON FOR NO HORMONE THERAPY	ABDOMINAL INFECTION	ABSCESS	ADMISSION FOR NEUTROPENIA	ANASTOMOTIC DEHISCENCE	DEHYDRATION	DIARRHEA	EARLY BOWEL OBSTRUCTION	PERINEAL INFECTION	PNEUMONIA (COL)	PROCTITIS	CONVERTED	CONVERTED STAGED BY FIELDS	CONVERTED TNM FIELDS	PULMONARY EMBOLISM (COL)	RADIATION ENTERITIS	STOMA COMPLICATION	URINARY TRACT INFECTION	ENDOCAVITARY RADIATION (ECRT)	INTRA-OPERATIVE RAD THERAPY	PRIMARY TUMOR RAD DOSE (cGy)	NUMBER OF RADIATION TREATMENTS	ADJUVANT CHEMOTHERAPY (COL)	5 FU (FLUOROURACIL)	SCREENING DATE	LEUCOVORIN	LEVAMISOLE	CPT 11	OTHER ADJUVANT THERAPY	DURATION OF ADJUVANT THERAPY	COMPLETED DURATION OF THERAPY	NUTRITIONAL CONSULTATION	OCCUPATIONAL THERAPY	OSTOMY CONSULTATION	PSYCHOSOCIAL	PATIENT ADDRESS AT DX	CITY/TOWN AT DX	PATIENT ADDRESS AT DX - SUPP	RADIATION TREATMENT	HISTORY OF LEUKEMIA (FAM)	HISTORY OF NON-HODGKIN'S LYMPH	HISTORY OF HODGKIN'S LYMPHOMA	1ST PRIMARY SITE	1ST PRIMARY HISTOLOGY	2ND PRIMARY SITE	2ND PRIMARY HISTOLOGY	ORGAN TRANSPLANT	HIV POSITIVE	CROHN'S DISEASE	COMPLETED BY	HASHIMOTO'S THYROIDITIS	SYSTEMIC LUPUS ERYTHEMATOSUS	RHEUMATOID ARTHRITIS	PNEUMOCYSTIS CARINII	CMV INFECTION	TUBERCULOSIS	MYCOBACTERIUM AVIUM	OTHER PARASITIC INFECTIONS	OTHER CONGENITAL DISEASES	OPPORTUNISTIC DISEASE	REVIEWED BY CANCER COMMITTEE	PREVIOUS CHEMOTHERAPY	PREVIOUS RADIATION THERAPY	AIDS RISK CATEGORY	CT SCAN OF BRAIN	CT SCAN OF ABDOMEN/PELVIS	MRI OF CHEST	MRI OF ABDOMEN/PELVIS	GALLIUM SCAN	AFIP/JPC SUBMISSION	LUMBAR PUNCTURE	HEMOGLOBIN/HEMATOCRIT	WHITE COUNT	PLATELET COUNT	LACTIC DEHYDROGENASE (LDH)	LIVER FUNCTION STUDIES (NHL)	TOTAL PROTEIN/ALBUMIN	GENE REARRANGEMENTS	REVIEW OF PATHOLOGY/OTHER INST	LYMPH NODE BIOPSY	PCE INDICATOR	BONE MARROW BIOPSY	CSF CYTOLOGY	OTHER SITE BIOPSY	SYSTEMIC SYMPTOMS	CD4 COUNT	HIV VIRAL LOADS	SPECIFIC HISTOLOGIC INFO	CELL TYPE OF LYMPHOMA	PATIENT STATUS AT DIAGNOSIS	TYPE OF STAGING SYSTEM (PED)	PATHOLOGIC T	PEDIATRIC STAGE	STAGED BY (PEDIATRIC STAGE)	EXTRANODAL SITE 1	EXTRANODAL SITE 2	EXTRANODAL SITE 3	EXTRANODAL SITE W/C-D SURGERY	EXTRANODAL SITE SURGICAL PROC	LYMPH NODES ABOVE DIAPHRAGM	LYMPH NODES BELOW DIAPHRAGM	PATHOLOGIC N	OTHER EXTRANODAL SITE(S)	TOTAL BODY	RADIATION/CHEMO SEQUENCE	PROTOCOL	SYSTEMIC CHEMOTHERAPY	SYSTEMIC CHEMOTHERAPY DATE	SYSTEMIC CHEMOTHERAPY CYCLES	CHLORAMBUCIL	CYCLOPHOSPHAMIDE (NHL)	DOXORUBICIN (NHL)	PATHOLOGIC M	FLUDARABINE	CHOP	CVP	COMLA	MACOP-B	M-BACOD	PRO-MACE-Cyta BOM	OTHER SYSTEMIC CHEMO AGENTS	HIGH DOSE SYSTEMIC CHEMO	INTRATHECAL CHEMOTHERAPY	STAGE GROUP PATHOLOGIC	PURPOSE OF INTRATHECAL CHEMO	INTERFERON (NHL)	INTERLEUKIN-2 (IL-2) (NHL)	MONOCLONAL ANTIBODIES	VACCINE THERAPY	STAGED BY (PATHOLOGIC STAGE)	TNM PATHOLOGIC	POSTAL CODE AT DX	DATE CASE COMPLETED	DAUGHTER (BR98)	MATERNAL AUNT (BR98)	MATERNAL GRANDMOTHER (BR98)	MOTHER (BR98)	ONE SISTER (BR98)	MORE THAN ONE SISTER (BR98)	FATHER (BR98)	BROTHER (BR98)	FAM HISTORY BREAST CA (BR98)	HISTORY OF BREAST CA (BR98)	ABSTRACT STATUS	SYNCHRONOUS BREAST CA (BR98)	COLON (BR98)	OVARY (BR98)	UTERUS (BR98)	PROSTATE (BR98)	OTHER (BR98)	HORMONE REPLACEMENT TPY (BR98)	HORMONE REPLACEMENT YRS (BR98)	UNKNOWN MAMMOGRAM (BR98)	UNKNOWN MAMMOGRAM DT (BR98)	ABSTRACTED BY	SCREENING MAMMOGRAM (BR98)	SCREENING MAMMOGRAM DT (BR98)	DIAGNOSTIC MAMMOGRAM (BR98)	DIAGNOSTIC MAMMOGRAM DT (BR98)	MAGNIFICATION MAMMOGRAM (BR98)	MAGNIFICATION MAMM DT (BR98)	MAMMOGRAM (BR98)	ULTRASOUND (BR98)	MOST DEFINITIVE MAMM (BR98)	DATE OF PATHOLOGIC DX (BR98)	OTHER T	DCSI ALSO PRESENT (BR98)	ARCHITECTURE PATTERN (BR98)	NUCLEAR GRADE (BR98)	SKIN INVOLVEMENT (BR98)	CHEST WALL INVOLVEMENT (BR98)	PECTORAL INVOLVEMENT (BR98)	DERMAL/LYMPHATIC INV (BR98)	DNA INDEX/PLOIDY (BR98)	REPORTING DATE	ANDROGEN RECEPTOR (BR98)	TYPE OF TEST (BR98)	SIZE OF DCIS TUMOR (MM) (BR98)	SENTINEL NODE BIOPSY	SENTINEL NODES EXAMINED (BR98)	SENTINEL NODES POSITIVE (BR98)	SENTINEL NODES DETECTED (BR98)	SPECIMEN RADIOGRAPH (BR98)	SUBMITTED TO PATHOLOGY (BR98)	MARGIN DISTANCE (BR98)	LAST TUMOR STATUS	V STATUS/LAST TUMOR STATUS	RE-EXCISION (BR98)	MICROSCOPIC STATUS (BR98)	PRE-RADIATION MAMMOGRAM (BR98)	SITES IRRADIATED (BR98)	cGy DOSE TO BREAST (BR98)	SPECIFIC HORMONE THPY (BR98)	CHEMOTHERAPY REGIME (BR98)	PSA DATE	ABSTRACT INCOMPLETE	OTHER N	OTHER M	REGIONAL TX MODALITY CONV FLAG	TYPE OF FIRST RECUR CONV FLAG	STAGED BY CONV FLAG	SURGICAL MARGINS CONV FLAG	STAGE FLAG	SCOPE OF LN SURGERY CONV FLAG	SURGICAL PROC/OTHER CONV FLAG	DATE OF DIAGNOSIS FLAG	RX DATE SURG DISCH FLAG	RX DATE-RADIATION FLAG	RX DATE RAD ENDED FLAG	RX DATE SYSTEMIC FLAG	RX DATE-CHEMO FLAG	RX DATE-HORMONE FLAG	RX DATE-BRM FLAG	RX DATE-OTHER FLAG	RX DATE-DX/STG PROC FLAG	DATE CONCLUSIVE DX FLAG	RECURRENCE DATE-1ST FLAG	DATE OF LAST CONTACT FLAG	SUBSQ RX 2ND CRS DATE FLAG	SUBSQ RX 3RD CRS DATE FLAG	SUBSQ RX 4TH CRS DATE FLAG	ADDRESS AT DX--STATE	ADDRESS AT DX--COUNTRY	ADDRESS CURRENT--STATE	ADDRESS CURRENT--POSTAL CODE	ADDRESS CURRENT--COUNTRY	DATE OF MULT TUMORS FLAG	DATE OF FIRST CONTACT FLAG	DATE OF INPT ADM FLAG	DATE OF INPT DISCH FLAG	DATE 1ST CRS RX FLAG	RX DATE-SURGERY FLAG	RX DATE MST DEFN SRG FLAG